![]() | Kevin Daniel MullenShow email addressDepartment of Internal Medicine, West Virginia University School of Medicine, Morgantown, WV, USA | West Virginia University, Morgantown, WV, USA | Division of ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Kevin Daniel Mullen:Expert Impact
Concepts for whichKevin Daniel Mullenhas direct influence:Hepatic encephalopathy,Chronic hepatitis,Portacaval shunt,Portal pressure,Portacaval anastomosis,Cirrhotic patients,Liver disease,Extracellular water.
Kevin Daniel Mullen:KOL impact
Concepts related to the work of other authors for whichfor which Kevin Daniel Mullen has influence:Hepatic encephalopathy,Chronic hepatitis,Liver disease,Cirrhotic patients,Metabolic syndrome,Portal hypertension,Hepatocellular carcinoma.
KOL Resume for Kevin Daniel Mullen
Year | |
---|---|
2019 | Department of Internal Medicine, West Virginia University School of Medicine, Morgantown, WV, USA |
2018 | West Virginia University, Morgantown, WV, USA |
2017 | Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Cleveland, OH, USA Dr Pantham is a clinical instructor of medicine at Case Western University in Cleveland, Ohio, and a hospitalist in the Department of Medicine at the University Hospitals Cleveland Medical Center in Cleveland, Ohio. Dr Mullen is the section chief of digestive diseases and a professor of medicine at the West Virginia University School of Medicine in Morgantown, West Virginia. |
2016 | Division of Gastroenterology, Metrohealth Medical Center, Case Western Reserve University, Cleveland, OH, USA |
2015 | MetroHealth Medical Center, Liver Research Section Case Western Reserve University Cleveland OH. Case Western Reserve University School of Medicine, Cleveland, US |
2014 | Case Western Reserve University Division of Gastroenterology, MetroHealth Medical Center Cleveland OH |
2013 | Case Western Reserve University School of Medicine, Cleveland, Ohio Gastroenterology Department Metrohealth Medical Center Cleveland OH USA |
2012 | Division of Gastroenterology and Hepatology, Case Western Reserve University, Cleveland, Ohio |
2011 | Division of Gastroenterology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA Metro Health Medical Center, Cleveland, OH |
2010 | Division of Gastroenterology, MetroHealth Medical Center, Case Western Reserve University, 2500 MetroHealth Drive, Cleveland, OH 44109, USA; Professor of Medicine Case Western Reserve University Director, Gastroenterology Fellowship Program Department of Gastroenterology MetroHealth Medical Center Cleveland, Ohio. Metrohealth Medical Center, Case Western Reserve University, Cleveland (K.D.M.), and University of Cincinnati Medical Center, Cincinnati (G.N.) — both in Ohio |
2009 | MetroHealth Medical Center, Division of Gastroenterology |
2008 | Division of Gastroenterology, MetroHealth Medical Center, Case Western University, Cleveland, Ohio |
2007 | Department of Gastroenterology/Hepatology, MetroHealth Medical Center, Cleveland, OH, USA |
2006 | Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH Division of Gastroenterology, MetroHealth Medical Center, Cleveland, Ohio |
2005 | Case Western Reserve School of Medicine, Cleveland, Ohio |
2004 | From the *Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, Virginia and the †Cleveland HCV Consortium, Cleveland, Ohio. Case Western Reserve University, Cleveland, OH |
2003 | Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio 44109, USA. Division of Gastroenterology (KDM), MetroHealth Medical Center, Cleveland, Ohio, USA |
2002 | FRCPI, GI Division, 6th Floor, Bell Greve Building, MetroHealth Medical Center, 2500 MetroHealth Dr, Cleveland, OH 44109‐1998. Telephone: 216‐778‐2235; FAX: 216‐778‐4873 Liver Transplant Center, Cleveland Clinic Foundation, Cleveland, OH Departments of Gastroenterology, The Cleveland Clinic Foundation, Cleveland, Ohio |
2001 | Gastrointestinal Division, Department of Medicine, MetroHealth Medical Center, 2500 MetroHealth Drive, Bell Greve Building, 44109-1998, Cleveland, OH, USA |
2000 | Division of Gastroenterology, Metro Health Medical Center, Case Western Reserve University, Cleveland, Ohio |
1999 | Case Western Reserve University, Cleveland, Ohio |
1998 | MetroHealth Medical Center, Case Western Reserve University (KDM), Cleveland, Ohio Departments of Medicine and Pediatrics, Case Western Reserve University, Cleveland, OH |
1997 | Department of Medicine, MetroHealth Medical Center, Cleveland, Ohio, USA From Case Western Reserve University, Metrohealth Medical Center, Cleveland, Ohio, U.S.A. |
1996 | Gastroenterology Division, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA Department of Gastrointestinal and Liver Diseases, Academic Medical Centre, Amsterdam |
1995 | Staff Gastroenterologist Associate Professor of Medicine Case Western Reserve University Cleveland, OH |
1994 | MetroHealth Medical Center, 2500 MetroHealth Drive, Room W603, Cleveland, Ohio 44109–1998, USA Brain Research Laboratory, Case Western Reserve University, Cleveland, OH. |
1993 | Division of Gastroenterology Department of Medicine MetroHealth Medical Center Case Western Reserve University Cleveland, Ohio, USA |
1992 | Departments of Medicine and Pediatrics, Case Western Reserve University, Cleveland, Ohio, USA |
1991 | Liver Disease Section, NIDDK, National Institutes of Health, Bethesda, Maryland. Gastroenterology Division, MetroHealth Medical Center, Cleveland, Ohio, USA Department of Medicine, Case Western Reserve University, Cleveland, Ohio 44109 |
1990 | Department of Neurological Surgery, State University of New York, Stony Brook, New York, USA Liver Diseases Section, Digestive Diseases Branch, NIDDK, National Institutes of Health, 20892, Bethesda, Maryland Division of Gastroenterology, Cleveland Metropolitan General Hospital, Cleveland, OH, U.S.A. |
1989 | Division of Gastroenterology Cleveland Metropolitan General Hospital Case Western Reserve University Cleveland, Ohio 44109 Liver Diseases Section, Digestive Diseases Branch, NIDDK National Institutes of Health, 20892, Bethesda, Maryland |
Concept | World rank |
---|---|
life rifamycins | #1 |
persistent cognitive defects | #1 |
cirrhosis broad range | #1 |
neuropsychiatric disorder patients | #1 |
brain receptors benzodiazepines | #1 |
“therapeutic studies | #1 |
justification placebocontrolled trials | #1 |
disorder encephalopathy humans | #1 |
pcm encephalopathy humans | #1 |
correlation ammonia levels | #1 |
resolution severe forms | #1 |
cirrhosis nitrogen | #1 |
cirrhosis patient quality | #1 |
flumazenil animal models | #1 |
dehydration constipation | #1 |
hospitalization retrospective | #1 |
latest data easl | #1 |
brain uptake 3h | #1 |
decades major problem | #1 |
mhe cardiovascular hepatic | #1 |
shunting addition | #1 |
hepatic encephalopathy decades | #1 |
sections outcome parameters | #1 |
concomitant lactulose | #1 |
apparent increase density | #1 |
70 kda composition | #1 |
precipitants hospitalization | #1 |
superimposed viral hepatitis | #1 |
cpss presence | #1 |
amantadine 200 | #1 |
minimal hepatic bottle | #1 |
symptoms mhe | #1 |
ammonia crucial role | #1 |
encephalopathy transfer | #1 |
alcoholic cirrhosis abstinence | #1 |
enteric bacteria neomycin | #1 |
referred hcv | #1 |
hepatic encephalopathy terminology | #1 |
efficacy bz antagonists | #1 |
pharmaceutical bzs | #1 |
clinical scales tests | #1 |
gabaergic tone mechanisms | #1 |
neurologic conditions epilepsy | #1 |
hepatic encephalopathy enemy | #1 |
rifaximin reduced | #1 |
therapy ammonia generation | #1 |
Sign-in to see all concepts, it's free! | |
Prominent publications by Kevin Daniel Mullen
BACKGROUND: Hepatic encephalopathy is a chronically debilitating complication of hepatic cirrhosis. The efficacy of rifaximin, a minimally absorbed antibiotic, is well documented in the treatment of acute hepatic encephalopathy, but its efficacy for prevention of the disease has not been established.
METHODS: In this randomized, double-blind, placebo-controlled trial, we randomly assigned 299 patients who were in remission from recurrent hepatic encephalopathy resulting from chronic ...
Known for Hepatic Encephalopathy | Rifaximin Treatment | Patients Placebo | Hazard Ratio | Risk Hospitalization |
BACKGROUND: There are several known predictors of an incomplete colonoscopy or difficult colonoscopy. In addition, inadequate bowel preparation has been reported in procedures scheduled later in the day. Operator fatigue, which tends to be higher as the day passes on, may also impact colonoscopy completion rate.
AIMS: To determine the influence of performing outpatient colonoscopies in the afternoon versus morning on the completion rates of colonoscopy and adequacy of bowel ...
Known for Afternoon Colonoscopies | Patients Morning | Incomplete Colonoscopy | Inadequate Bowel Preparation | Higher Failure Rates |
Measurements of total body and extracellular water in cirrhotic patients with and without ascites
[ PUBLICATION ]
Using H2[18O] tracer isotope dilution and corrected bromide space as standard reference techniques, we determined total body water and extracellular water in cirrhotic patients with (four men and four women) and without (seven men and six women) ascites and compared them with a normal control group (eight men and six women). These results were then compared with calculations of total body and extracellular water determined by the bioelectrical impedance analysis technique. According to ...
Known for Cirrhotic Patients | Extracellular Water | Total Body | Bioelectrical Impedance | Ascites Controls |
PURPOSE: Because the correlation between ammonia levels and the severity of hepatic encephalopathy remains controversial, we prospectively evaluated the correlation in 121 consecutive patients with cirrhosis.
METHODS: The diagnosis of hepatic encephalopathy was based on clinical criteria, and the severity of hepatic encephalopathy was based on the West Haven Criteria for grading of mental status. Arterial and venous blood samples were obtained from each patient. Four types of ammonia ...
Known for Hepatic Encephalopathy | Ammonia Levels | Partial Pressure | Illness Statistics | Venous Blood |
In an attempt to improve the efficacy of antiviral therapy for chronic hepatitis C, a three-drug combination of pegylated interferon α-2b, ribavirin, and amantadine has been suggested. Despite the initial enthusiasm, the role of amantadine in the treatment of chronic hepatitis C remains controversial. In a multi-center, open-label clinical trial, the potential efficacy and safety of this triple combination regimen were assessed. In this open-label pilot study, two separate patient ...
Known for Chronic Hepatitis | Ribavirin Amantadine | Patients Genotypes | 24 Weeks | Response Svr |
Three separate, but allosterically interacting, sites on the gamma-aminobutyric acid (GABA) supramolecular complex in the brain were pharmacologically blocked in rabbits with hepatic encephalopathy due to galactosamine-induced fulminant hepatic failure to determine whether decreased GABAergic neurotransmission can ameliorate the syndrome of hepatic encephalopathy. Bicuculline (a GABAA receptor blocker), Ro 15-1788 (a benzodiazepine receptor antagonist), or isopropylbicyclophosphate (a ...
Known for Hepatic Encephalopathy | Benzodiazepine Receptor | Rabbit Model | Visual Evoked | Increased Resistance |
Triple Combination of Interferon Alpha-2b, Ribavirin, and Amantadine for Treatment of Chronic Hepatitis C
[ PUBLICATION ]
Retreatment of interferon-resistant chronic hepatitis C represents a significant clinical challenge. In an open-label, pilot study, the safety and efficacy of interferon alpha-2b, ribavirin, and amantadine were assessed. Twenty patients with chronic hepatitis C who had previously failed to respond to a course of interferon monotherapy followed by a course of combination therapy (10 patients received interferon alpha-2b [3 million units three times a week] plus ribavirin [800 mg/d] and 10 ...
Known for Chronic Hepatitis | Ribavirin Amantadine | 24 Weeks | Combination Therapy | Interferon Alpha |
The role of the GABA-benzodiazepine receptor complex in the pathogenesis of hepatic encephalopathy was investigated by recording the electrophysiological responses of single cerebellar Purkinje neurons from rabbits with hepatic encephalopathy due to galactosamine-induced fulminant hepatic failure. Both the GABAmimetic muscimol and the benzodiazepine receptor agonist flunitrazepam were 3-4 times more potent in depressing the spontaneous activity of Purkinje neurons from rabbits with ...
Known for Hepatic Encephalopathy | Animal Model | Benzodiazepine Receptor | Neurons Gaba | Control Rabbits |
BACKGROUND: Superimposed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) may affect HCV-related fibrosis. We performed a study to determine the relationship between NAFLD and chronic hepatitis C.
METHODS: One hundred and twenty patients with chronic hepatitis C and available liver biopsies were included. Baseline liver biopsies were read by 1 hepatopathologist using Metavir, as well as a fatty liver pathology protocol. Patients' baseline clinical, ...
Known for Fatty Liver | Chronic Hepatitis | Steatosis Patients | Obesity Bmi | Hcv Genotype |
BACKGROUND/AIMS: Interferon-based regimens (alone or with ribavairin) are standard therapies for chronic hepatitis C. The aim of this study was to compare a 24-week regimen of interferon alpha-2b + ribavirin (IFN + RIBA) to interferon alpha-2b + amantadine (IFN + AMANT) in non-responders to previous interferon monotherapy.
METHODS: In a multi-center, double-blind clinical trial, 118 patients (non-responders to previous interferon monotherapy) were equally randomized into the two arms: ...
Known for Interferon Monotherapy | Amantadine Treatment | Chronic Hepatitis | Alpha2b Ribavirin | Controlled Trial |
Portacaval anastomosis causes delayed growth, decreased testes and liver weights, and elevated estradiol serum levels in male rats compared with sham-operated controls. Female rats treated with portacaval anastomosis grow at a normal rate despite changes in liver weight and estradiol levels similar to those observed in the male rats. This study examined the pituitary gonadal axis in both genders in this animal model. The rats receiving portacaval anastomosis were compared with both ...
Known for Portacaval Anastomosis | Male Rats | Food Intake | Growth Hormone | Rat Model |
Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B
[ PUBLICATION ]
Forty-five patients with chronic hepatitis B were entered into a randomized controlled trial of recombinant human alpha-interferon therapy. All patients had hepatitis B surface antigen in serum for at least 1 yr and had stable serum levels of both hepatitis B virus deoxyribonucleic acid and hepatitis B e antigen. During the 4-mo period of therapy, 10 of 31 (32%) treated patients and only 1 of 14 (7%) control patients became negative for serum hepatitis B virus deoxyribonucleic acid and ...
Known for Chronic Hepatitis | Interferon Patients | Recombinant Human Α | Controlled Trial | Topic Dna |
BACKGROUND: Hepatic encephalopathy (HE) is a brain disorder that often results from cirrhosis due to viral hepatitis, metabolic and alcohol-related liver disease, and is characterised by cognitive, psychiatric and motor impairments. Recurrent bouts of overt HE negatively impact daily functioning and quality of life.
AIM: To evaluate the effect of rifaximin on health-related quality of life (HRQL) in cirrhotic patients with HE.
METHODS: Patients with cirrhosis in remission from HE (Conn ...
Known for Hepatic Encephalopathy | Cirrhotic Patients | Health‐related Quality | Life Hrql | Illness Surveys |
Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease
[ PUBLICATION ]
OBJECTIVE: Thrombocytopenia or leukopenia in patients with chronic liver disease is often attributed to functional overactivity of the spleen (hypersplenism). Despite being a fairly common phenomenon, there is a paucity of reports on the prevalence of this syndrome in stable chronic liver disease patients with or without severe fibrosis/cirrhosis. The aim of this study was to establish the prevalence of peripheral blood cytopenia in patients with nonalcoholic cirrhosis/severe fibrosis ...
Known for Patients Cirrhosis | Chronic Liver | Platelet Count | Peripheral Blood Cytopenia | Mild Fibrosis |
Early Hepatitis C virus–RNA responses predict interferon treatment outcomes in chronic hepatitis C
[ PUBLICATION ]
In previous studies employing interferons (IFNs) in the treatment of chronic hepatitis C, there have been few reliable predictors of sustained responses. We retrospectively evaluated the predictive value of hepatitis C virus (HCV)-RNA measurements in the first few months during consensus interferon (CIFN) treatment using a sensitive reverse-transcriptase polymerase chain reaction assay to determine sustained responses. Data from two large treatment trials, one of IFN-naive patients and ...
Known for Chronic Hepatitis | Interferon Treatment | Hcv Rna | Sustained Responses | 6 Months |